Skip to main content
. 2018 Jun 29;8:9846. doi: 10.1038/s41598-018-28253-9

Figure 1.

Figure 1

Survival analysis stratified by LOXL2 expression levels in pancreatic cancer (PC) cases from The Cancer Genome Atlas (TGCA) datasets. (A) Kaplan-Meier Analysis for recurrence-free survival (RFS) stratified by LOXL2 expression. (B) Kaplan-Meier Analysis for overall survival (OS) stratified by LOXL2 expression. Both RFS and OS of PC cases with high LOXL2 expression were significantly worse than the cases with low LOXL2 according to the log-rank test.